Please login to the form below
Oesophageal cancer
This page shows the latest Oesophageal cancer news and features for those working in and with pharma, biotech and healthcare.
NIHR awards £2.3m for AI study to improve radiotherapy for lung cancer
new standard of care for lung cancer patients receiving radiotherapy to treat their disease. ... Study results may also benefit other cancers affecting the chest area such as lymphoma or oesophageal cancer in the future.".
Latest news
-
Bristol Myers Squibb’s Opdivo recommended by NICE for rare gastroesophageal cancers
By attaching to PD-1, Opdivo blocks its action and allows the body’s immune system to continue to attack the gastric, oesophageal or gastro-oesophageal junction cancer cells. ... recommend this innovative treatment for people with these rare forms of
-
University of Cambridge launches Early Cancer Institute for complex cancers
The test has been proven to detect oesophageal cancer in time for it to be treated, and involves patients being administered a pill that dissolves into a sponge. ... Given that only one in eight oesophageal cancer patients (12%) survive for ten or more
-
BeiGene announces positive phase 3 trial results for liver cancer treatment
There were more than 900, 000 new cases in 2020 of the most common type of primary liver cancer – unresectable hepatocellular carcinoma. ... Japan. Last month, Novartis announced positive results from a phase 3 trial showing tislelizumab plus
-
Novartis announces positive phase 3 trial results for advanced oesophageal cancer
Novartis has announced positive results from a phase 3 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) for patients with advanced oesophageal cancer, regardless of PD-L1 status. ... The treatment is currently
-
AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
Small cell lung cancer accounts for 15% of all lung cancers and has a poor prognosis. ... tract cancer, oesophageal cancer, gastric and gastroesophageal cancer, cervical cancer, ovarian cancer, endometrial cancer, and other solid tumours.
More from news
Approximately 8 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... Other important read-outs in first-line kidney, oesophageal and gastric cancer are also due this year, as well as
-
Chinese biotech’s global ambitions
has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal
-
Deal Watch March 2016
Acquisition of royalty rights. $1, 140. Blueprint Medicines/ Roche. Small molecules targeting kinases for cancer immunotherapy. ... Collaboration – marketing &distribution. $171. AVEO Oncology/ CANbridge Life Sciences. AV-203; ErbB3 (HER3) inhibitory
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Syneos Health®
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
